Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy | MicrobiomeTrials← Back to trialsNCT07750678
Safety and Efficacy Study of GEB-101 Injection in Subjects With TGFBI-related Corneal Dystrophy
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-10Est. Completion: 2027-08
Enrollment target: 30 participants Locations- University of California, Los Angeles (UCLA), Los Angeles, California, United States
- Fudan University Eye & ENT Hospital, Shanghai, Shanghai Municipality, China
Other microbiome trials you might be interested in
Fuchs Endothelial Corneal DystrophyCataractGlaucoma
The goal of this study is to learn if topical ROCK inhibitors protect endothelial corneal cells in patients with glaucom…
Zagreb, CroatiaCompleted Dec 1, 2026
Fuchs Endothelial Corneal Dystrophy
This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stre…
Boston, United StatesEst. completion Apr 29, 2027